NASDAQ:KROS

Keros Therapeutics Stock News

Healthcare > Biotechnology

Buy KROS

*Your capital is at risk

$11.15

+0.500 (+4.69%)

At Close: Aug 07, 2026

Did Keros Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - KROS

11:00am, Sunday, 22'nd Dec 2024

NEW YORK, NY / ACCESSWIRE / December 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concer

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation

10:00am, Sunday, 22'nd Dec 2024

NEW YORK, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NAS

Levi & Korsinsky Reminds Keros Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - KROS

10:30am, Friday, 20'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concer

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation

10:00am, Friday, 20'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NAS

Levi & Korsinsky Announces an Investigation on Behalf of Keros Therapeutics, Inc. (KROS) Shareholders Who May Have Been Affected by Fraud

10:15am, Thursday, 19'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concer

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

10:00am, Thursday, 19'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NAS

ATTENTION KROS SHAREHOLDERS: Investors who lost money on Keros Therapeutics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

10:15am, Wednesday, 18'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concer

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect

10:00am, Wednesday, 18'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NAS

Keros Therapeutics: Trading At Essentially Cash Value, Target Of $23 Per Share

07:10am, Wednesday, 18'th Dec 2024

Keros Therapeutics' stock plummeted due to safety concerns in its Phase 2 TROPOS trial, but the risk-reward profile remains favorable for a rebound. The stock's enterprise value dropped drastically, n

Lost Money on Keros Therapeutics, Inc.(KROS)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

10:55am, Tuesday, 17'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concer

Keros Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - KROS

10:30am, Tuesday, 17'th Dec 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS

10:30am, Tuesday, 17'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investors are

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Stockholders to Connect

10:00am, Tuesday, 17'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NAS

Shareholders that lost money on Keros Therapeutics, Inc.(KROS) should contact Levi & Korsinsky about Securities Fraud Investigation - KROS

01:15pm, Monday, 16'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concer

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS  

12:45pm, Monday, 16'th Dec 2024

NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investors are

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by